$0.44
1.67% day before yesterday
Nasdaq, Dec 27, 10:01 pm CET
ISIN
US85209E1091
Symbol
SPRB
Sector
Industry

Spruce Biosciences Inc Stock price

$0.44
-0.11 19.90% 1M
-0.09 17.79% 6M
-2.49 85.07% YTD
-2.27 83.86% 1Y
-3.77 89.61% 3Y
-14.56 97.08% 5Y
-14.56 97.08% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.01 1.67%
ISIN
US85209E1091
Symbol
SPRB
Sector
Industry

Key metrics

Market capitalization $18.07m
Enterprise Value $-38.76m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.83
EV/Sales (TTM) EV/Sales -5.46
P/S ratio (TTM) P/S ratio 2.55
P/B ratio (TTM) P/B ratio 0.35
Revenue growth (TTM) Revenue growth -1.40%
Revenue (TTM) Revenue $7.10m
EBIT (operating result TTM) EBIT $-43.24m
Free Cash Flow (TTM) Free Cash Flow $-46.50m
Cash position $60.06m
EPS (TTM) EPS $-0.96
P/E forward negative
P/S forward 3.55
EV/Sales forward negative
Short interest 0.08%
Show more

Is Spruce Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Spruce Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Spruce Biosciences Inc forecast:

5x Hold
100%

Analyst Opinions

5 Analysts have issued a Spruce Biosciences Inc forecast:

Hold
100%

Financial data from Spruce Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.10 7.10
1% 1%
100%
- Direct Costs 0.05 0.05
83% 83%
1%
7.05 7.05
2% 2%
99%
- Selling and Administrative Expenses 14 14
15% 15%
200%
- Research and Development Expense 36 36
24% 24%
508%
-43 -43
18% 18%
-608%
- Depreciation and Amortization 0.05 0.05
83% 83%
1%
EBIT (Operating Income) EBIT -43 -43
18% 18%
-609%
Net Profit -39 -39
20% 20%
-555%

In millions USD.

Don't miss a Thing! We will send you all news about Spruce Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Spruce Biosciences Inc Stock News

Negative
Reuters
18 days ago
Spruce Biosciences said on Tuesday it will wind down investments for its genetic disorder drug after it failed to meet the main goal in a mid-stage study.
Neutral
Business Wire
18 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in ...
Neutral
Business Wire
about 2 months ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2024 and provided corporate updates. “We remain on track to ...
More Spruce Biosciences Inc News

Company Profile

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.

Head office United States
CEO Javier Szwarcberg
Employees 29
Founded 2014
Website www.sprucebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today